These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 8613931)
1. Reversible inhibition of rat gastric H+/K+-ATPase by T-330, 2-[2-dimethylaminobenzyl)sulfinyl]-1-(3-methylpyridine-2-yl)imidazole. Kinoshita M; Saito N; Noto T; Tamaki H J Pharmacol Exp Ther; 1996 Apr; 277(1):28-33. PubMed ID: 8613931 [TBL] [Abstract][Full Text] [Related]
2. 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors. Yamada M; Yura T; Morimoto M; Harada T; Yamada K; Honma Y; Kinoshita M; Sugiura M J Med Chem; 1996 Jan; 39(2):596-604. PubMed ID: 8558532 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Gedda K; Briving C; Svensson K; Maxvall I; Andersson K Biochem Pharmacol; 2007 Jan; 73(2):198-205. PubMed ID: 17081503 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacological characteristics of a newly synthesized H+-K+ ATPase inhibitor, YJA20379-1, 2-amino-4,5-dihydro-8-phenylimidazole[2,1-b]thiazolo[5,4-g]benzothiazol e. Sohn SK; Chang MS; Choi WS; Kim KB; Woo TW; Lee SB; Chung YK Can J Physiol Pharmacol; 1999 May; 77(5):330-8. PubMed ID: 10535682 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of gastric H,K-ATPase activity and gastric epithelial cell IL-8 secretion by the pyrrolizine derivative ML 3000. Smolka AJ; Goldenring JR; Gupta S; Hammond CE BMC Gastroenterol; 2004 Feb; 4():4. PubMed ID: 15028114 [TBL] [Abstract][Full Text] [Related]
7. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms. Fryklund J; Wallmark B J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo. Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921 [TBL] [Abstract][Full Text] [Related]
9. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands. Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447. Ushiro T; Tsukimi Y; Tanaka H Jpn J Pharmacol; 1997 Nov; 75(3):303-6. PubMed ID: 9434264 [TBL] [Abstract][Full Text] [Related]
12. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). Puscas I; Coltau M; Baican M; Domuta G J Pharmacol Exp Ther; 1999 Aug; 290(2):530-4. PubMed ID: 10411559 [TBL] [Abstract][Full Text] [Related]
13. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. Nagaya H; Satoh H; Kubo K; Maki Y J Pharmacol Exp Ther; 1989 Feb; 248(2):799-805. PubMed ID: 2537417 [TBL] [Abstract][Full Text] [Related]
14. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats. Kinoshita M; Saito N; Tamaki H Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044 [TBL] [Abstract][Full Text] [Related]
15. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219 [TBL] [Abstract][Full Text] [Related]
16. Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase. Zimmermann PJ; Buhr W; Brehm C; Palmer AM; Feth MP; Senn-Bilfinger J; Simon WA Bioorg Med Chem Lett; 2007 Oct; 17(19):5374-8. PubMed ID: 17723299 [TBL] [Abstract][Full Text] [Related]
17. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo. Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the gastric H+,K+ -ATPase by plectrinone A, a diterpenoid isolated from Plectranthus barbatus Andrews. Schultz C; Bossolani MP; Torres LM; Lima-Landman MT; Lapa AJ; Souccar C J Ethnopharmacol; 2007 Apr; 111(1):1-7. PubMed ID: 17166678 [TBL] [Abstract][Full Text] [Related]
19. Omeprazole: mode of action and effect on acid secretion in animals. Wallmark B Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():101-6. PubMed ID: 2657278 [TBL] [Abstract][Full Text] [Related]
20. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]